Clinical Trial Outcomes for Cardiac Myosin Inhibitors in oHCM Treatment
An expert in cardiology shares clinical trial findings of emerging and approved cardiac myosin inhibitors for the treatment of oHCM.
Source: hcplive.com
Explorer Hcm News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Explorer Hcm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Explorer Hcm Today - Breaking & Trending Today
Dr Milind Desai Highlights New Findings From VALOR-HCM Trial
After 16 weeks on placebo, patients in the control group were invited to start mavacamten alongside the treatment group, explained Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.
Source: ajmc.com
Clinical benefits of mavacamten demonstrated in patients with symptomatic obstructive hypertrophic cardiomyopathy
1. Mavacamten demonstrated substantial enhancement in alleviating valsalva left ventricular outflow tract (LVOT) obstruction in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) compared to placebo, with favorable tolerability. 2. Additionally, all secondary measures of effectiveness, including New York Heart Association (NYHA) functional class, health status, cardiac biomarkers, and cardiac structure, displayed improvements. Evidence Rating
Source: 2minutemedicine.com